Just In
- 8 hrs ago Heeramandi Screening: Alia Bhatt, Ananya Panday, Rashmika Mandanna And Others Serve Finest Ethnic Style!
- 8 hrs ago From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By
- 11 hrs ago Exclusive: On World Malaria Day 2024, Dr Shares Danger Signs Parents Must Watch Out For In Child With Malaria
- 11 hrs ago Exclusive: Expert Debunks 5 Common Misconceptions About Expectant Mothers That You Need To Steer Clear From
Don't Miss
- News Harvey Weinstein's Conviction Overturned, Netizens Angered Over Elite Privilege
- Finance 3 Bonus, 1:2 Split, 38 Dividends: Rs 1,915 Midcap IT Stock To Pay 360% Dividend After Q4 Profit Rises
- Movies Arti Singh Wedding: Groom Dipak Chauhan’s First Look Out As He Reaches Venue With Baraat - VIRAL VIDEOS
- Sports T20 World Cup 2024: Waqar Younis Predicts Pakistan's 15-Man Squad; Drops This Express Pacer
- Automobiles Royal Enfield Unveils Revolutionary Rentals & Tours Service: Check Out All Details Here
- Technology Elon Musk’s X Is Launching a TV App Similar to YouTube for Watching Videos
- Education AICTE introduces career portal for 3 million students, offering fully-sponsored trip to Silicon Valley
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Phase III Trials Of Covid Drug Movfor Show Positive Results, Says Hetero
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
The results, presented as an Oral Abstract at the Conference on Retroviruses and Opportunistic Infections (CROI) held virtually February 12-16, 2022, demonstrated that Molnupiravir along with the standard of care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug, the Hyderabad-based drugmaker said in a statement.
No fatalities were reported during the study, it added.
Under the Phase III trials, one of the studies included 1,218 COVID-19 patients, it said. The study enrolled eligible patients, within five days of symptom onset, were administered with Molnupiravir capsules(800 mg twice daily) for five days, it added.
Hetero entered into a non-exclusive voluntary licensing agreement with MSD in April 2021 for the manufacturing and distribution of Molnupiravir for the treatment of COVID-19.
Under this licensing deal, Hetero was allowed to expand access to Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies.
- pregnancy parentingMysterious Pneumonia Outbreak In China: What Are The Long-Term Effects Of Pneumonia In Children?
- healthCan You Get Back COVID-Related Loss Of Sense Of Smell And Taste (Parosmia)? Looks Like You Can!
- healthDid Covid-10 Vaccination Increase Risk Of Sudden Deaths In Young Adults? ICMR Finds This..
- wellnessDelhi Air Pollution, Air Quality Very Poor: Do Covid Masks Help Reduce Pollution Side Effects?
- healthNobel Prize 2023: Scientists Behind The COVID-19 mRNA Vaccines Wins
- healthWhat Is Disease X? 20 Times More Deadlier Than Covid 19; Can Cause 50 Million Deaths, Does It Have Vaccine?
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- healthDo You Pick Your Nose? Stop! It Can Increase COVID Risk
- healthEris Variant: WHO Alarms New Covid Wave; Should India Be Concerned About This Pandemic
- healthVitamin D Deficiency Linked With Increased Risk Of Long COVID
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- healthCOVID-19: IMA Cites 3 Reasons Behind Recent Surge In Covid-19 Cases: What Are They?